Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01423851 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1 study of Primary Myelofibrosis and Post-Essential Thrombocythemia Myelofibrosis, sponsored by NS Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 77
- Enrollment target
- 9
- Study locations
NCT01423851 is a Phase 1 study of Primary Myelofibrosis and Post-Essential Thrombocythemia Myelofibrosis that has completed, run by NS Pharma. The registered enrollment target is 77 participants, below the 118-participant average among 30 other Primary Myelofibrosis trials with a reported enrollment target (35% lower). The trial reports 9 study locations across 8 states.
The verdict
NCT01423851, a Phase 1 study of Primary Myelofibrosis and Post-Essential Thrombocythemia Myelofibrosis, has completed, sponsored by NS Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 77 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to determine the safety and tolerability of orally administered NS-018 in patients with Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (post-ET MF)
Conditions Studied
Interventions
- DRUG NS-018
Study Locations (9)
Illinois
- Northwestern University - Chicago
- University of Chicago - Chicago
Arizona
- Mayo Clinic Scottsdale Recruiting - Scottsdale
California
- UC San Diego Moores Cancer Center - San Diego
Florida
- Mayo Clinic, Jacksonville - Jacksonville
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- University of Michigan - Ann Arbor
New York
- Weill Cornell Medical College - New York
Texas
- MD Anderson Cancer Center, Department of Leukemia - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2011-06 |
| Est. Completion | 2020-04-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01423851
The ClinicalTrials.gov registry entry for NCT01423851 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 118-participant average among 30 other Primary Myelofibrosis trials with a reported enrollment target (35% lower). The listed sponsor is NS Pharma, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Primary Myelofibrosis appearing as the primary indexed condition, and to 1 intervention - of which NS-018 is the first listed.
NCT01423851 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Illinois, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT01423851 about?
NCT01423851 is a clinical study titled "Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF". The purpose of this study is to determine the safety and tolerability of orally administered NS-018 in patients with Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (post-ET MF)
What is the current status of trial NCT01423851?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2011-06. Estimated completion is 2020-04-22.
What conditions does trial NCT01423851 study?
This clinical trial studies the following conditions: Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, Post-Polycythemia Vera Myelofibrosis.
What interventions are being tested in trial NCT01423851?
The interventions under investigation include: NS-018 (DRUG).
Who is sponsoring clinical trial NCT01423851?
This trial is sponsored by NS Pharma, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01423851 being conducted?
This trial has 9 study locations across Arizona, California, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
RECRUITING · Phase 1
-
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
-
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
RECRUITING · Phase 1
-
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
RECRUITING · Phase 1
-
Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
RECRUITING · Phase 1
Explore more on PlainTrial
Primary Myelofibrosis
All registered trials for this condition
Post-Essential Thrombocythemia Myelofibrosis
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.